particles], provided that <u>each of</u> said [substance] <u>one or more substances</u> is selected from the group consisting of a C_8-C_{16} fatty acid, a salt of such a fatty acid, a salt of glycyrrhizine acid, an acyl carnitine, and an alkyl saccharide.

43. (Amended) The composition of claim 42, wherein the composition contains only [said active compounds] <u>(A) and (B)</u>.

44. (Amended) The composition of claim 42, wherein the composition contains[, in addition to said active compounds,] <u>a non-hygroscopic additive which is</u> a pharmaceutically acceptable carrier.

45. (Amended) The composition of claim 42, wherein [said substance] <u>at least one of said one or more substances</u> is selected from the group consisting of [a] sodium, potassium and lysine [salt] <u>salts</u> of caprylic acid (C_8), capric acid (C_{10}), lauric acid (C_{12}), and myristic acid (C_{14}).

49. (Amended) The composition of claim 42, wherein [said substance] <u>at least one of said one or more substances</u> is selected from the group consisting of an alkyl glucoside and alkyl maltoside.

50. (Amended) The composition of claim 42, wherein [said substance] at least one of said one or more substances is selected from the group consisting of a decyl glucoside, dodecyl glucoside, decyl maltoside, and dodecyl maltoside.

51. (Amended) The composition of claim 42, wherein [said substance] at least one of said one or more substances is selected from the group consisting of [a] sodium and potassium [salt] salts of glycyrrhizine acid.

E4 cont

52. (Amended) The composition of claim 42, wherein [said substance] at least one of said one or more substances is selected from the group consisting of decanoyl carnitine, lauryl carnitine, myristoyl carnitine, and palmitoyl carnitine.

E5

53. (Amended) The composition of claim 42, in which at least 50 % of [the dry powder] the total mass of (A) and (B) consists of [(a)] primary particles having a diameter of between 1 and 6 microns [or (b) agglomerates of such particles].

54. (Amended) The composition of claim 42, wherein the ratio of (A) to (B) [in said mixture] is in the range of 9:1 to 1:1.

60. (Amended) The composition of claim 42, wherein said polypeptide is selected from the group consisting of a growth factor, interleukin, polypeptide vaccine, enzyme, endorphin, glycoprotein, lipoprotein, and polypeptide involved in the blood coagulation cascade[, that exerts its pharmacological effect systemically].

E6

63. (Amended) A [pharmaceutical] composition [comprising a mixture of active compounds] consisting essentially of (A) a [pharmaceutically active] polypeptide [and], (B) [a phospholipid which enhances] one or more phospholipids that enhance the absorption of said polypeptide in the lower respiratory tract, and (C) optionally one or more non-hygroscopic additives, said [mixture] composition being in the form of a [non-hygroscopic] dry powder suitable for inhalation from a dry powder inhaler, wherein at least 50% of the total mass of [said active compounds] (A) and (B) consists of [(a)] primary particles having a diameter of up to about 10 microns [or (b) agglomerates of such particles].

E7

64. (Amended) The composition of claim 63, wherein the composition contains only said [active compounds] polypeptide and said one or more phospholipids.

E8

65. (Amended) The composition of claim 63, wherein the composition contains[, in addition to said active compounds,] a

non-hygroscopic additive which is a pharmaceutically acceptable carrier.

66. (Amended) The composition of claim 63, wherein [said phospholipid] at least one of said one or more phospholipids is selected from the group consisting of diacylphosphatidylcholine, diacylphosphatidylglycerol, diacylphosphatidylethanolamine, diacylphosphatidylinositol, and diacylphosphatidylserine.

E8 cont

67. (Amended) The composition of claim 63, wherein [said phospholipid] at least one of said one or more phospholipids is dioctanoylphosphatidylglycerol or dioctanoylphosphatidylcholine.

68. (Amended) The composition of claim 63, in which at least 50% of the [dry powder] total mass of said polypeptide and said one or more phospholipids consists of [(a)] primary particles having a diameter of between 1 and 6 microns [or (b) agglomerates of such particles].

69. (Amended) The composition of claim 63, wherein the ratio of (A) to (B) [in said mixture] is in the range of 9:1 to 1:1.

---

72. (Amended) The composition of claim 63, wherein said polypeptide is selected from the group consisting of a growth

E9

factor, interleukin, polypeptide vaccine, enzyme, endorphin, glycoprotein, lipoprotein, and polypeptide involved in the blood coagulation cascade[, that exerts its pharmacological effect systemically].

E 9 Cont

75. (Amended) The composition of claim 63, wherein [said phospholipid] at least one of said one or more phospholipids is a single-chain phospholipid.

76. (Amended) The composition of claim 75, wherein [said phospholipid] at least one of said one or more phospholipids is selected from the group consisting of lysophosphatidylcholine, lysophosphatidylglycerol, lysophosphatidylethanolamine, lysophosphatidylinositol, and lysophosphatidylserine.

E 10

77. (Amended) The composition of claim 75, wherein [said phospholipid] at least one of said one or more phospholipids is palmitoylphosphatidylglycerol or palmitoylphosphatidylcholine.

78. (Amended) The composition of claim 75, wherein the composition contains only [said active compounds] (A) and (B).

79. (Amended) The composition of claim 75, wherein the composition contains[, in addition to said active compounds,] a